291 related articles for article (PubMed ID: 28089247)
21. [Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)].
Bolanowski M; Jarzab B; Handkiewicz-Junak D; Jeziorski A; Kos-Kudła B; Zajecki W;
Endokrynol Pol; 2008; 59(1):87-96. PubMed ID: 18335403
[TBL] [Abstract][Full Text] [Related]
22. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
23. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.
Neychev V; Kebebew E
Int J Surg Oncol; 2017; 2017():6424812. PubMed ID: 28593056
[TBL] [Abstract][Full Text] [Related]
24. An update on gastroenteropancreatic neuroendocrine tumors.
Cives M; Strosberg J
Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
26. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
27. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
28. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
31. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
Basu B; Sirohi B; Corrie P
Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
[TBL] [Abstract][Full Text] [Related]
32. [Digestive neuroendocrine tumors].
de Mestier L; Deguelte-Lardière S; Brixi H; Kianmanesh R; Cadiot G
Rev Med Interne; 2016 Aug; 37(8):551-60. PubMed ID: 26897113
[TBL] [Abstract][Full Text] [Related]
33. [Neuroendocrine pancreatic tumors and helpfulness of targeted therapies].
Vaysse T; Coriat R; Perkins G; Dhooge M; Brezault C; Chaussade S
Presse Med; 2013 Jun; 42(6 Pt 1):961-7. PubMed ID: 23009947
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
35. [A TNM classification for digestive endocrine tumors of midgut and hindgut: proposals from the European Neuroendocrine Tumor Society (ENETS)].
Couvelard A; Scoazec JY
Ann Pathol; 2007 Dec; 27(6):426-32. PubMed ID: 18554552
[TBL] [Abstract][Full Text] [Related]
36. [Neuroendocrine tumors of the small bowels are on the rise: early tumors and their management].
Scherübl H; Schwertner C; Steinberg J; Stölzel U; Pohl J; Dralle H; Klöppel G
Z Gastroenterol; 2010 Mar; 48(3):406-13. PubMed ID: 20183784
[TBL] [Abstract][Full Text] [Related]
37. Treatment of liver metastases in patients with digestive neuroendocrine tumors.
Rossi RE; Massironi S; Spampatti MP; Conte D; Ciafardini C; Cavalcoli F; Peracchi M
J Gastrointest Surg; 2012 Oct; 16(10):1981-92. PubMed ID: 22829240
[TBL] [Abstract][Full Text] [Related]
38. Management of Small Bowel Neuroendocrine Tumors.
Scott AT; Howe JR
Surg Oncol Clin N Am; 2020 Apr; 29(2):223-241. PubMed ID: 32151357
[TBL] [Abstract][Full Text] [Related]
39. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
40. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
Ganetsky A; Bhatt V
Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
